United States Food and Drug Administration (USFDA) granted approval to Semglee, an insulin glargine injection co-developed by Biocon Limited and Mylan N.V, which will be in vial and pre-filled pen presentations form used to keep in check high blood sugar in adults with type 2 diabetes, and adult and pediatric patients with type 1 diabetes.